A common complaint from “Canadian capitalists” is that we need to be more like our American counterparts. Well, we got what we asked for but not what we wanted, with obesity on the rise in Canada according to a new study.

Just like our neighbours, we look for the easy way out - making the coming semaglutide (ozempic) patent expiry an interesting catalyst for Loblaw (L), as lower cost generics get the green light and the addressable market expands (both in size and waistline).

But Loblaw’s pharmacy segment (Shoppers Drug Mart) has been crushing it for some time, with same-store sales growth tracking well ahead of the traditional grocer business, resulting in a fat premium to peers… it’s probably priced in.

About Bullpen: Bullpen Finance Inc. publishes content on Canadian markets and provides paid research coverage of select Canadian issuers. Bullpen is paid in cash by covered issuers, does not accept stock or options, does not hold positions in covered securities, and does not conduct investment banking business. Bullpen and LodeRock Advisors Inc. are affiliated; LodeRock provides investor relations services to issuers, some of whom are covered by Bullpen Research. When a post discusses a covered issuer, a specific disclosure appears at the top of the post. This post is published for general information purposes. It is not personalized investment advice and is not tailored to any individual reader’s circumstances. Bullpen is not a registered investment adviser or dealer. For full disclosures, including analyst certification, jurisdictional statements, and conflict of interest policies, please see our Legal & Disclosures section on our website.

You might be interested in…